{"doi":"10.1016/j.cardfail.2023.05.009","title":"Association Between Change in Ambulatory Pulmonary Artery Pressures and Natriuretic Peptides in Patients with Heart Failure: Results From the EMBRACE-HF Trial","abstract":"BACKGROUND: Remote monitoring of pulmonary artery (PA) pressures and serial N-terminal pro-B-type natriuretic peptide (NT-proBNP) measurements guide heart failure (HF) treatment, but their association has yet to be described. METHODS AND RESULTS: In the Empagliflozin Evaluation by Measuring the Impact on Hemodynamics in Patients with Heart Failure (EMBRACE-HF) trial, patients with HF and a remote PA pressure monitoring device were randomized to empagliflozin vs placebo. PA diastolic pressures (PADP) and NT-proBNP levels were obtained at baseline and 6 and 12 weeks. We used linear mixed models to examine the association between change in PADP and change in NT-proBNP, adjusting for baseline covariates. Of 62 patients, the mean patient age was 66.2 years, and 63% were male. The mean baseline PADP was 21.8 ± 6.4 mm Hg, and the mean NT-proBNP was 1844.6 ± 2767.7 pg/mL. The mean change between baseline and averaged 6- and 12-week PADP was -0.4 ± 3.1 mm Hg, and the mean change between baseline and averaged 6- and 12-week NT-proBNP was -81.5 ± 878.6 pg/mL. In adjusted analyses, every 2-mm Hg decrease in PADP was associated with an NT-proBNP reduction of 108.9 pg/mL (95% confidence interval -4.3 to 222.0, P = .06). CONCLUSIONS: We observed that short-term decreases in ambulatory PADP seem to be associated with decreases in NT-proBNP. This finding may provide additional clinical context when tailoring treatment for patients with HF.","journal":"Journal of Cardiac Failure","year":2023,"id":362216,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":8,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9624,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":280741,"name":"Dan Nguyen","orcid":"0000-0002-9590-0655","position":1,"is_corresponding":false},{"id":31026,"name":"John A. Spertus","orcid":"0000-0002-2839-2611","position":2,"is_corresponding":false},{"id":312386,"name":"Kensey Gosch","orcid":"0000-0003-2934-6913","position":3,"is_corresponding":false},{"id":744135,"name":"Fengming Tang","orcid":null,"position":4,"is_corresponding":false},{"id":1026589,"name":"Sheryl L. Windsor","orcid":"0000-0003-0909-4309","position":5,"is_corresponding":false},{"id":312388,"name":"Philip G. Jones","orcid":"0000-0002-7136-4464","position":6,"is_corresponding":false},{"id":1115326,"name":"Yevgeniy Khariton","orcid":"0000-0001-9215-5023","position":7,"is_corresponding":false},{"id":702293,"name":"Andrew J. Sauer","orcid":"0000-0002-9268-2795","position":8,"is_corresponding":false},{"id":57284,"name":"Mikhail Kosiborod","orcid":"0000-0002-3750-9789","position":9,"is_corresponding":false},{"id":636404,"name":"Michael E. Nassif","orcid":"0000-0002-1232-7604","position":0,"is_corresponding":true}],"reference_count":9,"raw_metadata":null,"created_at":"2026-07-19T01:14:19.266946Z","pmid":"37230315","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}